12.1 Vascular Anomalies & Benign Neonatal Dermatoses

12.1 Vascular Anomalies & Benign Neonatal Dermatoses

The ISSVA Classification Framework: Tumours vs. Malformations

The diagnosis and therapeutic triage of neonatal and paediatric vascular lesions underwent a paradigm shift following the biological classification originally proposed by Mulliken and Glowacki in 1982, now codified and updated by the International Society for the Study of Vascular Anomalies (ISSVA, 2018). Vascular anomalies are fundamentally dichotomised into two biologically distinct categories:

1. Vascular Tumours: Characterised by true cellular hyperplasia and endothelial proliferation. These lesions demonstrate increased endothelial cell turnover, mast cell infiltration, and lobular expansion. While typically absent or diminutive at birth, they exhibit post-natal proliferative growth followed, in many types, by variable regression.
2. Vascular Malformations: Characterised by abnormal vascular morphogenesis without increased endothelial cellular turnover. They represent inborn structural errors of vascular embryogenesis (dysmorphology of capillaries, veins, lymphatics, or arteries). They are always present at birth (though they may not become clinically manifest until later in childhood or adolescence) and grow commensurately with the child, never undergoing spontaneous involution.

ISSVA Biological and Clinical Distinction Matrix

---

Infantile Haemangioma (IH)

Infantile Haemangioma (IH) is the most common benign soft-tissue tumour of childhood, occurring in 4% to 5% of Caucasian infants. Recognised risk factors include female sex (ratio 3–5:1), prematurity (especially birth weight <1500 g), multiple gestation, advanced maternal age, and chorionic villus sampling (CVS).

Life Cycle and Natural History

• Precursor Lesion (Birth): Often presents as a faint, pale, vasoconstricted macule with surrounding telangiectasias, an erythematous punctate blush, or an ecchymotic/bruised area.
• Proliferative Phase (0 to 9 Months): Rapid, non-linear growth during the first 3 to 6 months of life (80% of total growth occurs before 5 months of age). Superficial lesions become bright red, bosselated, and raised ("strawberry haemangioma"); deep lesions present as warm, soft, bluish subcutaneous masses; mixed lesions possess both components.
• Plateau Phase (9 to 12 Months): Tumour growth stabilises, matching the growth rate of the infant.
• Involution Phase (1 to 7+ Years): The lesion softens, darkens to a violaceous or dull grey hue, and flattens centripetally. The older rule of thumb that "about 10% involutes per year" overstates the timescale: most involution is complete by about 3 to 4 years of age. Post-involution residual sequelae (common, especially in thick or deep lesions) include fibrofatty tissue accumulation, anetoderma-like wrinkling, scarring, and persistent telangiectasias.

Immunohistochemical Hallmark: GLUT-1

Infantile haemangiomas demonstrate diffuse, intense, cytoplasmic immunoreactivity for erythrocyte-type glucose transporter protein 1 (GLUT-1) across all phases of development and involution. GLUT-1 is shared with placental trophoblast microvessels, Lewis Y antigen, merosin, and Fc-gamma-RII, supporting the theory that IH may originate from embolised placental tissue or early primitive endothelial progenitor cells. In contrast, vascular malformations and all congenital haemangiomas are strictly GLUT-1 negative.

Clinical Complications and Triage

Approximately 10% to 15% of IHs require urgent specialist intervention due to complications:

1. Ulceration: The single most common complication (15%), typically occurring during the peak proliferative phase (age 4–6 months). Predilection sites include the perineum, perioral region, and skin folds. Ulceration causes intractable pain, secondary bacterial infection, bleeding, and permanent scarring.
2. Visual Axis Obstruction (Amblyopia): Periocular/periorbital IH can induce permanent amblyopia via visual axis occlusion (deprivation amblyopia), direct compression of the globe causing corneal distortion (astigmatic amblyopia), or orbital infiltration leading to strabismus and proptosis.
3. Airway Obstruction (Subglottic Haemangioma): Segmental haemangiomas involving the mandibular or lower facial distribution ("beard distribution": lower lip, chin, mandible, anterior neck) carry a 60% risk of concurrent subglottic haemangioma, presenting as biphasic stridor, croup-like barking cough, and progressive respiratory failure between 6 and 12 weeks of age.
4. Anatomical and Cartilaginous Distortion: Lesions of the nasal tip ("Cyrano haemangioma"), lips, columella, and earlobes lead to destructive cartilage splaying and permanent disfigurement.
5. High-Output Cardiac Failure: Extensive hepatic haemangiomatosis (multiple cutaneous lesions accompanied by hepatic vascular tumours) creates profound arteriovenous or portovenous shunting, leading to hepatomegaly, congestive cardiac failure, and consumptive hypothyroidism (due to tumoral type 3 iodothyronine deiodinase activity degrading thyroid hormones).

---

A Critical Pitfall: Kasabach-Merritt Phenomenon (KMP)

Key distinction: Kasabach-Merritt phenomenon does not occur in infantile haemangioma. Confusing IH with KMP leads to wrong management decisions.

Kasabach-Merritt Phenomenon (KMP) is a catastrophic, consumptive coagulopathy defined by profound thrombocytopenia (platelets often <20 × 10⁹/L), hypofibrinogenemia, elevated D-dimers, and microangiopathic hemolytic anemia. It is caused by severe intralesional platelet trapping and activation within anomalous, slit-like vascular channels.

• Causative Vascular Tumours: KMP occurs exclusively within Kaposiform Hemangioendothelioma (KHE) or Tufted Angioma (TA).
• Clinical Presentation: An indurated, violaceous, ecchymotic, tense, infiltrative plaque or tumor with advancing purpuric margins, characteristically located on the retroperitoneum, trunk, or proximal extremities of a neonate or young infant.
• Management: First-line pharmacotherapy is the oral mTOR inhibitor Sirolimus (rapamycin), often combined with systemic corticosteroids or vincristine. Platelet transfusions are strictly contraindicated unless life-threatening hemorrhage occurs, as transfused platelets are immediately sequestered, aggravating tumoral expansion and consumptive coagulopathy.

---

Syndromic Segmental Haemangiomas: PHACE and LUMBAR

Haemangiomas presenting in a segmental (plaque-like, dermatomal) distribution rather than focal/nodular carry a high risk of underlying congenital neurovascular and visceral malformations.

1. PHACE Syndrome

Large segmental infantile haemangiomas (>5 cm) of the face, scalp, or neck mandate formal multidisciplinary evaluation for PHACE Syndrome:

• P (Posterior fossa brain malformations): Dandy-Walker malformation, cerebellar hypoplasia, arachnoid cysts.
• H (Haemangioma): Large, segmental, plaque-like facial haemangioma (predominantly involving frontonasal, maxillary, or mandibular segments V1–V3).
• A (Arterial cerebrovascular anomalies): Dysgenesis, hypoplasia, aplasia, stenosis, or aneurysmal dilatation of the internal carotid and vertebral basilar arteries, persistence of embryonic vessels (e.g., trigeminal artery).
• C (Cardiac defects and aortic coarctation): Coarctation of the aorta (characteristically complex transverse arch coarctation), interrupted aortic arch, ventricular septal defects (VSD).
• E (Eye abnormalities): Microphthalmia, optic nerve hypoplasia, persistent fetal vasculature, exophthalmos, iris coloboma.
• Additional Feature (S): Sternal clefting or supraumbilical abdominal raphe (referred to as PHACES syndrome).

Mandatory Diagnostic Workup: MRI/MRA of the brain, head, and neck (to evaluate posterior fossa and intracranial arteries); transthoracic echocardiography with aortic arch visualization; detailed dilated ophthalmologic examination.

2. LUMBAR (PELVIS / SACRAL) Syndrome

Segmental haemangiomas localized to the lower body, lumbosacral region, perineum, or buttocks are associated with occult spinal dysraphism and urogenital abnormalities:

• LUMBAR: Lower body haemangioma, Urogenital anomalies / Ulceration, Myelopathy (tethered spinal cord, lipomyelomeningocele), Bony deformities, Anorectal malformations, Renal abnormalities.
• PELVIS: Perineal haemangioma, External genitalia malformations, Lipomyelomeningocele, Vesicorenal abnormalities, Imperforate anus, Skin tag.
• Mandatory Diagnostic Workup: Magnetic resonance imaging (MRI) of the spine and pelvis (or spinal ultrasound if age <3–4 months before posterior vertebral arches ossify) to rule out tethered cord and intraspinal extension.

---

Congenital Haemangiomas: RICH, NICH, and PICH

Congenital haemangiomas are distinct vascular tumours that are fully formed at birth and do not exhibit post-natal accelerated endothelial proliferation. They are universally GLUT-1 negative.

1. Rapidly Involuting Congenital Haemangioma (RICH):
   • Solitary, violaceous, dome-shaped or plaque-like mass with prominent radial veins, peripheral pale halo, and central ulceration or depression.
   • Undergoes rapid, spontaneous involution starting immediately after birth, achieving near-complete regression by 12 to 14 months of age, leaving atrophic, fibrofatty tissue.
2. Non-Involuting Congenital Haemangioma (NICH):
   • Well-demarcated pink-to-violaceous plaque or exophytic tumor with coarse, overlying telangiectasias, a distinct pale border, and central warmth.
   • Persists indefinitely without regression, growing proportionately with the child throughout life. Treatment, if symptomatic, is surgical excision or pulsed dye laser for surface telangiectasias.
3. Partially Involuting Congenital Haemangioma (PICH):
   • Manifests initially with partial regression resembling a RICH, but involution arrests prematurely, leaving a stable lesion clinically and histologically identical to a NICH.

---

Vascular Malformations: Classification by Flow Velocity

Vascular malformations arise from defective embryologic morphogenesis and are subclassified based on fluid hemodynamics:

1. Slow-Flow Malformations

• Capillary Malformation (Port-Wine Stain / Naevus Flammeus):
  • Flat, sharply demarcated, pink-red macular patch present at birth that darkens to a deep purple, thickens, and develops vascular nodules (cobblestoning) in adulthood.
  • Caused by somatic mosaic activating mutations in GNAQ (p.Arg183Gln) or GNA11.
  • Sturge-Weber Syndrome (Encephalotrigeminal Angiomatosis): High risk when the port-wine stain involves the V1 (ophthalmic) division of the trigeminal nerve (forehead and upper eyelid). Manifests with ipsilateral leptomeningeal angiomatosis (causing intractable epilepsy, progressive ischemic stroke-like episodes, developmental delay, and cortical tram-track calcification on CT/MRI) and congenital or juvenile glaucoma (elevated episcleral venous pressure or trabecular dysgenesis). Treatment of skin: Pulsed dye laser (PDL, 595 nm).
  • Klippel-Trenaunay Syndrome (KTS): Low-flow combined capillary-venous-lymphatic malformation associated with soft tissue and bony hypertrophy of an extremity (most commonly lower extremity) and anomalous lateral embryonic veins (vein of Servelle). Caused by somatic mosaic mutations in PIK3CA (part of the PIK3CA-Related Overgrowth Spectrum / PROS).
• Venous Malformation (VM):
  • Soft, compressible, non-pulsatile bluish subcutaneous nodules or masses that swell with dependency or Valsalva manoeuvre. Pain arises from thrombosis leading to round, calcified phleboliths visible on plain radiography or MRI.
  • Driven by somatic mutations in the endothelial tyrosine kinase receptor TEK (TIE2) or PIK3CA.
  • Blue Rubber Bleb Nevus Syndrome (Bean Syndrome): Multiple tender, cutaneous "rubber bleb" venous malformations associated with extensive gastrointestinal venous malformations, resulting in chronic iron-deficiency anemia from occult GI hemorrhage.
• Lymphatic Malformation (LM):
  • Subdivided into macrocystic (>2 cm cysts; cystic hygroma of the neck/axilla) and microcystic (clusters of translucent vesicles resembling "frog spawn", frequently complicated by intralesional bleeding and lymphorrhea).

2. Fast-Flow Malformations

• Arteriovenous Malformation (AVM) and Arteriovenous Fistula (AVF):
  • Direct communication between arteries and veins bypassing the capillary bed. Present clinically as warm, pink-red, pulsatile masses with a palpable thrill and continuous audible bruit.
  • Classified by the Schobinger clinical staging system: Stage I (quiescence: pink warm patch resembling PWS), Stage II (expansion: tortuosity, thrill, bruit), Stage III (destruction: ulceration, bleeding, pain, necrosis), Stage IV (decompensation: high-output congestive heart failure).
  • Driven by somatic mutations in MAP2K1 or germline RASA1/EPHB4 (capillary malformation-AVM syndrome).

---

European Consensus Management of Infantile Haemangioma

The discovery in 2008 by Léauté-Labrèze and colleagues that beta-adrenergic antagonists induce rapid involution revolutionized IH therapeutics, displacing systemic corticosteroids as first-line treatment.

Mechanism of Action of Beta-Blockers

Propranolol acts via three complementary pathways:

1. Early Phase (Hours to Days): Vasoconstriction secondary to local release of nitric oxide reduction, causing palpable softening and lightening of the lesion.
2. Intermediate Phase (Weeks): Downregulation of pro-angiogenic growth factors including VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor) via the MAPK/ERK signaling pathway.
3. Late Phase (Months): Induction of endothelial cell apoptosis and recruitment of tissue inhibitors of metalloproteinases, accelerating fibrofatty replacement.

European Treatment Guidelines and Protocol

• First-Line Systemic Therapy: Oral Propranolol Hydrochloride (approved by the EMA as an oral paediatric formulation at 3.75 mg/mL).
• Indications for Treatment:
  1. Life-threatening complications (subglottic/tracheal obstruction, high-output cardiac failure).
  2. Functional impairment (periocular IH impeding vision, external auditory canal occlusion, lip/feeding compromise).
  3. Active or impending ulceration with severe pain.
  4. High risk of permanent disfigurement (nasal tip, lip columella, large facial segmental lesions).
• Therapeutic Dosing Schedule:
  • Initiation: Start at 1 mg/kg/day divided into two doses.
  • Titration: Increase after 1 to 2 weeks to the target maintenance dose of 2 to 3 mg/kg/day (standard consensus maintenance: 2.0 to 3.0 mg/kg/day administered in two divided doses spaced at least 9 hours apart).
  • Administration Rule: Must be administered during or immediately following a milk feed.
• Contraindications: Sinus bradycardia, second- or third-degree atrioventricular (AV) block, cardiogenic shock, hypotension, active bronchospasm / bronchial hyperreactivity (asthma), hypersensitivity to propranolol, and neonates with corrected gestational age <5 weeks.
• Mandatory Pre-Treatment Screening: Clinical cardiovascular examination (heart rate, blood pressure, cardiac auscultation for murmurs). Routine electrocardiogram (ECG) is indicated only if baseline heart rate is below age-adjusted normal, if an arrhythmia is auscultated, or if there is a personal/family history of congenital heart disease or long QT syndrome. In patients with facial segmental IH, PHACE syndrome must be ruled out with brain/neck MRA and echocardiogram prior to starting propranolol, as rapid blood pressure drop can precipitate acute cerebral infarction in the presence of severe arch coarctation or intracranial arterial hypoplasia.
• Critical Adverse Effects & Safety Management:
  • Hypoglycemia: Propranolol blocks glycogenolysis, gluconeogenesis, and masks adrenergic hypoglycemic warning symptoms (tachycardia, tremor, agitation; diaphoresis is preserved). To prevent fatal hypoglycemia, propranolol must be withheld during acute intercurrent illnesses with poor feeding, vomiting, or diarrhea.
  • Bradycardia and Hypotension: Assessed during dose escalations; typically asymptomatic and transient.
  • Bronchospasm / Wheezing: Beta-2 receptor antagonism induces bronchoconstriction; withhold during acute viral bronchiolitis.
  • Sleep Disturbance: Night terrors, vivid dreams, somnolence, cold peripheral extremities.
• Treatment Duration: Maintained continuously until 12 to 15 months of age, spanning the natural proliferative phase. Tapering over 2 to 4 weeks prevents rebound regrowth (rebound occurs in 10–15% of cases, responding to re-initiation).
• Topical Beta-Blockers: Topical Timolol Maleate 0.5% gel-forming solution (1–2 drops twice daily) is reserved for small, superficial, thin (<1–2 mm), non-problematic haemangiomas where systemic absorption is negligible.

---

Benign Transient Neonatal Pustular Dermatoses

Neonatal pustular and vesicular eruptions represent common, anxiety-provoking presentations. A critical clinical competency is distinguishing benign, self-limiting sterile conditions from life-threatening neonatal infections (e.g., Neonatal Herpes Simplex Virus, Congenital Candidiasis, Staphylococcal Scalded Skin Syndrome, Listeriosis).

1. Erythema Toxicum Neonatorum (ETN)

• Incidence & Onset: The most common pustular eruption, affecting 40% to 50% of full-term neonates. Arises typically between 24 and 72 hours of life; rare in premature infants <35 weeks.
• Morphology & Distribution: Splotchy, erythematous macules (2–3 cm) with central 1–2 mm pale-yellow to white firm papules or pustules, producing a classic "flea-bite" appearance. Distributed over the chest, back, face, and proximal extremities. Strictly spares the palms and soles.
• Tzanck / Cytologic Smear: Wright-Giemsa or Gram stain of the pustule contents reveals a dense sheet of intact eosinophils (>90%); Gram stain demonstrates no bacteria.
• Pathogenesis & Prognosis: Sterile inflammatory response around the hair follicle infundibulum (innate immune response to initial microbial commensal colonization). Completely benign; resolves spontaneously within 7 to 14 days without treatment.

2. Transient Neonatal Pustular Melanosis (TNPM)

• Incidence & Onset: Present at birth in up to 5% of Black neonates and 0.5% of Caucasian neonates.
• Triphasic Evolution:
  1. Phase 1: Fragile, 2–4 mm superficial pustules or vesicopustules lacking surrounding erythema, present at delivery.
  2. Phase 2: Pustules rupture within 24–48 hours, leaving a delicate collarette of fine white scale surrounding a hyperpigmented macule.
  3. Phase 3: Non-inflammatory, pinpoint hyperpigmented brown macules that persist for several weeks to months before spontaneous resolution.
• Distribution: Chin, neck, forehead, lower back, and frequently involves the palms and soles (unlike ETN).
• Tzanck / Cytologic Smear: Aspiration of intact pustules reveals a predominance of neutrophils alongside cellular debris and rare eosinophils; sterile.

3. Miliaria (Eccrine Duct Occlusion)

Caused by retention of eccrine sweat due to occlusion of the sweat duct under conditions of warmth and high humidity:

• Miliaria Crystallina (Sudamina): Occlusion at the stratum corneum. Fragile, clear, non-inflammatory, superficial vesicles resembling "dewdrops" on normal skin without erythema. Rupture easily.
• Miliaria Rubra ("Prickly Heat"): Occlusion within the stratum spinosum (intraepidermal). Intensely pruritic, erythematous papules and tiny vesicles on an erythematous base located in intertriginous folds, neck, and trunk.
• Miliaria Profunda: Occlusion at the dermo-epidermal junction. Rare in neonates; firm, pale, flesh-colored non-inflammatory papules.

4. Neonatal Cephalic Pustulosis (Neonatal Malassezia Pustulosis)

• Onset & Morphology: Manifests at 2 to 4 weeks of age (not present at birth). Multiple tiny inflammatory papules and pustules scattered over the cheeks, forehead, chin, eyelids, and scalp.
• Etiology: Inflammatory host reaction to colonization with lipophilic yeasts of the genus Malassezia (M. sympodialis, M. furfur), stimulated by maternal androgens on infant sebaceous glands.
• Critical Distinction from True Infantile Acne: Neonatal cephalic pustulosis exhibits complete absence of comedones (no blackheads or whiteheads). In contrast, true Infantile Acne arises later (3 to 6 months), features open and closed comedones, inflammatory cysts, risks scarring, and requires endocrine evaluation if accompanied by virilisation or hirsutism.
• Management: Self-limiting, but rapidly resolves with topical 2% ketoconazole cream twice daily for 7 to 10 days.

---

Differential Diagnosis Matrix: Neonatal Pustular & Vesicular Dermatoses